GlaxoSmithKline will move the company’s experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing after experiencing encouraging mid-stage trial results.
Cambridge, Mass.-based Moderna announced the publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0.
GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data
Analysts, Business, Clinical Data, Endometrial Cancer, Fast Track Designation, FDA, Immunotherapies, Influenza, Multiple myeloma, Oncology, Ovarian Cancer, PARP Inhibitors, Pneumonia, Product Pipeline, Quarterly results, R&D, Respiratory Syncytial Virus, VaccinesIn GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
Novavax Inc.’s vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late-stage study.